Peripheral inflammation in spinocerebellar ataxia type 3: associations with genetic and clinical manifestations
- PMID: 41042292
- DOI: 10.1007/s00011-025-02102-8
Peripheral inflammation in spinocerebellar ataxia type 3: associations with genetic and clinical manifestations
Abstract
Background: Neuroinflammation plays a recognized role in the pathogenesis of Spinocerebellar Ataxia Type 3 (SCA3). However, the involvement of systemic inflammatory responses in SCA3 remains poorly defined.
Objectives: Our study aimed to characterize peripheral inflammation in patients with SCA3, examine the relationship between peripheral inflammatory biomarkers and clinical/genetic features, and evaluate the diagnostic utility of these markers.
Methods: The cross-sectional study enrolled 101 patients with SCA3 and 101 healthy controls (HCs). The differences in peripheral inflammatory markers between patients with SCA3 and HCs were assessed. Multivariate linear regressions were used to analyze the associations between blood cell count-derived indices, C-reactive protein (CRP), and clinical/genetic features of SCA3. ROC curves were conducted to assess the potential of these markers to distinguish patients with SCA3 from HCs.
Results: Compared to HCs, patients with SCA3 exhibited significantly higher levels of leukocytes, neutrophils, monocytes, platelets, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), systemic inflammatory index (SII), systemic inflammatory composite index (AISI), and CRP (adj. p < 0.05). Age influenced lgCRP, NLR, MLR, and lg(neutrophil-to-platelet ratio) (p < 0.05). CAG affected MLR and AISI (p < 0.05). The combination of BMI, monocytes, NLR, and SII differentiated patients with SCA3 from HCs (AUC = 0.779).
Conclusion: Patients with SCA3 display distinct peripheral inflammatory profiles, which correlate with clinical/genetic factors. These peripheral inflammatory markers hold promise as potential tools for diagnosing and monitoring SCA3.
Keywords: Biomarker; Blood cell count-derived inflammatory indices; Neuroinflammation; Peripheral Inflammation; Spinocerebellar ataxia type 3.
© 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. Consent to participate: Informed consent was obtained from all participants or their legal representatives. Ethics approval: Approval was obtained from the Ethics Committee of the First Affiliated Hospital of Fujian Medical University. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
References
-
- Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primers. 2019;5:24. https://doi.org/10.1038/s41572-019-0074-3 . - DOI - PubMed
-
- Ghanekar SD, Kuo SH, Staffetti JS, Zesiewicz TA. Current and emerging treatment modalities for spinocerebellar ataxias. Expert Rev Neurother. 2022;22:101–14. https://doi.org/10.1080/14737175.2022.2029703 . - DOI - PubMed - PMC
-
- Bettcher BM, Tansey MG, Dorothee G, Heneka MT. Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus. Nat Rev Neurol. 2021;17:689–701. https://doi.org/10.1038/s41582-021-00549-x . - DOI - PubMed - PMC
-
- Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson’s disease. Acta Neuropathol. 2021;141:527–45. https://doi.org/10.1007/s00401-021-02268-5 . - DOI - PubMed - PMC
-
- Subeta P, Lana AJ, Schlachetzki JCM. Chronic peripheral inflammation: a possible contributor to neurodegenerative diseases. Neural Regen Res. 2021;16:1711–4. https://doi.org/10.4103/1673-5374.306060 . - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
